Home

JOHN CRAIG THOMPSON

CIK 1509643 · President & CEO · last filed 2026-07-13

JOHN CRAIG THOMPSON is a President & CEO who has filed 25 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing, for ESPR, was dated Jul 13, 2026. Across all open-market trades the lifetime net is −$3.9M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

25

Lifetime Open-Market Net

-$3.93M

Filer Profile

Reported Address
C/O TRIUS THERAPEUTICS, INC.
6310 NANCY RIDGE DRIVE, SUITE 101
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Esperion Therapeutics, Inc. (ESPR) Delisted Director 0 $3.18 $0 $0 3 2026-07-13
Anthera Pharmaceuticals Inc (ANTH) Delisted President & CEO 19,848 — — $26.2K 9 2018-01-09
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Chief Operating Officer 517 — — -$3.96M 8 2015-09-10
Trius Therapeutics Inc (TSRX) Delisted Chief Commercial Officer 133 — — $862 4 2013-03-11

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-13 Esperion Therapeutics, Inc. (ESPR) Delisted Disp (D) −79,873 $0 EDGAR
2026-06-01 Esperion Therapeutics, Inc. (ESPR) Delisted Grant (A) +79,873 $0 EDGAR
2025-07-02 Esperion Therapeutics, Inc. (ESPR) Delisted Grant (A) — $0 EDGAR
2018-01-09 Anthera Pharmaceuticals Inc (ANTH) Delisted Grant (A) — $0 EDGAR
2017-09-20 Anthera Pharmaceuticals Inc (ANTH) Delisted Buy (P) +8,550 $11.3K EDGAR
2017-09-07 Anthera Pharmaceuticals Inc (ANTH) Delisted Buy (P) +10,400 $14.9K EDGAR
2017-09-07 Anthera Pharmaceuticals Inc (ANTH) Delisted Exer (M) +10,400 $14.9K EDGAR
2017-05-22 Anthera Pharmaceuticals Inc (ANTH) Delisted Grant (A) — $0 EDGAR
2017-03-03 Anthera Pharmaceuticals Inc (ANTH) Delisted Grant (A) — $0 EDGAR
2017-03-03 Anthera Pharmaceuticals Inc (ANTH) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.